Aortic stiffness in a mortality risk calculator for kidney transplant recipients

Transplantation

Volumn 99, Issue 8, 2015, Pages 1730-1737

  Dahle, Dag Olav ^a,e   Eide, Ivar Anders ^a   Åsberg, Anders ^a,b   Leivestad, Torbjørn ^a   Holdaas, Hallvard ^a   Jenssen, Trond Geir ^a,c   Fagerland, Morten W ^a   Pihlstrøm, Hege ^a   Mjøen, Geir ^a   Hartmann, Anders ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIURETIC AGENT; EVEROLIMUS; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; ANALYTICAL EQUIPMENT; ARTERIAL STIFFNESS; ARTICLE; CALIBRATION; CAROTID ARTERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMORAL ARTERY; FOLLOW UP; GOLD STANDARD; GRAFT RECIPIENT; HUMAN; INTERNAL VALIDITY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; OSCILLOMETER; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PULSE WAVE; RISK ASSESSMENT; SAMPLING; SURVIVAL TIME; TONOMETER; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; AGED; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MIDDLE AGED; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PULSE WAVE ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84942427907     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000660     Document Type: Article

References (42)

1. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419-1427.
2. Mansell H, Stewart SA, Shoker A. Validity of cardiovascular risk prediction models in kidney transplant recipients. Scientific World Journal. 2014;2014:750579.
3. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart. 2010;96:817-823.
4. Briet M, Burns KD. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond). 2012;123:399-416.
5. VanBortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotidfemoral pulse wave velocity. J Hypertens. 2012;30:445-448.
6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
7. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant metaanalysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636-646.
8. Verbeke F, Marechal C, Van Laecke S, et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension. 2011;58:833-838.
9. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellstrom B. A cardiovascular risk calculator for renal transplant recipients. Transplantation. 2012;94:57-62.
10. Soveri I, Snyder J, Holdaas H, et al. The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation. 2013;95:142-147.
11. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
12. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.
13. Newson RB. Comparing the predictive power of survival models using Harrell's C or Somer's D. Stata J. 2010;10:339.
14. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98:683-690.
15. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
16. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010; 121:505-511.
17. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
18. Steyerberg EW. Evaluation of performance. In: Clinical prediction models. New York: Springer; 2009.
19. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54:1328-1336.
20. Mattace-Raso FU, Hofman H, Verwoert GC, et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: "establishing normal and reference values". Eur Heart J. 2010;31:2338-2350.
21. Mitchell GF. Arterial stiffness and hypertension: chicken or egg? Hypertension. 2014;64:210.
22. Boutouyrie P, Lacolley P, Briet M, et al. Pharmacological modulation of arterial stiffness. Drugs. 2011;71:1689-1701.
23. Ait-Oufella H, Collin C, Bozec E, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28:2336-2341.
24. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011;29:1034-1042.
25. Laurent S, Boutouyrie P. Dose-dependent arterial destiffening and inward remodeling after Olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014;64:709-716.
26. Peters CD, Kjaergaard KD, Jensen JD, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int. 2014;86:625-637.
27. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2010;95:722-730.
28. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Peroxisome proliferator activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007;56:1396-1401.
29. Joannides R, Monteil C, de Ligny BH, et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant. 2011;11:2414-2422.
30. Cohen DL, Warburton KM, Warren G, Bloom RD, Townsend RR. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. Am J Hypertens. 2004;17:209-212.
31. Gelens MA, Christiaans MH, v Hooff JP. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Transplant Proc. 2005;37:1900-1901.
32. Martinez-Castelao A, Sarrias X, Bestard O, et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc. 2005;37:3788-3790.
33. Strozecki P, Adamowicz A, Wlodarczyk Z, Manitius J. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients. Ren Fail. 2007;29:679-684.
34. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and metaanalysis. The Lancet. 2013;382:1268-1277.
35. Kruger T, Brandenburg V, Schlieper G, Marx N, Floege J. Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant. 2013;28:534-541.
36. Mac-Way F, Poulin A, Utescu MS, et al. The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. Nephrol Dial Transplant. 2014;29:2113-2120.
37. Maizel J, Six I, Dupont S, et al. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int. 2013;84:491-500.
38. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24:842-852.
39. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327-1339.
40. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482-2494.
41. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Buhaescu I, Covic M. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation. 2003;76:1573-1577.
42. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.